Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes.
Peixun HeXiaolin LuoJiabei LiYi LiXiaozeng WangLan HuangJun JinYaling HanPublished in: Cardiovascular therapeutics (2021)
Ticagrelor did not improve the composite of nonfatal MI, target vessel revascularization, rehospitalization, stroke, and death from any cause; however, it significantly increased the incidence of bleeding events defined by the Bleeding Academic Research Consortium (BARC) criteria in Chinese patients with ACS and diabetes during the 6-month follow-up compared with clopidogrel.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- atrial fibrillation
- antiplatelet therapy
- type diabetes
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- cardiovascular disease
- glycemic control
- coronary artery bypass grafting
- coronary artery disease
- risk factors
- adipose tissue
- medical students